MetaBloQ logo — Innovative biotechnological advancements for targeting metab...

MetaBloQ

Innovative biotechnological advancements for targeting metabolic pathways in cancer cells.

Founded 2015 Seed Biopharma, Biotechnology +2

General Information

Company Name MetaBloQ
Founded Year 2015
Founders / Decision Makers
Team member
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with MetaBloQ. To contact MetaBloQ, visit metabloqpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About MetaBloQ

MetaBloQ is a promising biotechnology startup founded in 2015 with a focus on pioneering innovative biotechnological advancements for targeting metabolic pathways in cancer cells. The company's slogan, "Innovative biotechnological advancements for targeting metabolic pathways in cancer cells," encapsulates its ambitious mission. MetaBloQ is dedicated to developing new drugs that effectively block specific metabolic processes in cancer cells. With its primary focus lying in the Biopharma, Biotechnology, and Pharmaceutical industries, MetaBloQ's potential for growth and impact in the biotech sector is substantial. In January 2016, MetaBloQ secured a significant Seed Round investment from prominent investors including Brandon Capital Partners, Uniseed Ventures, and the Medical Research Commercialisation Fund (MRCF). This injection of funding underscores the confidence that key players in the investment community have in MetaBloQ's vision and potential to make a meaningful contribution to the field of biotechnology and its applications in cancer treatment.

Taxonomy: metabolic pathways, cancer, drug development, metabolic processes, cancer treatment, innovation, biotechnological advancements, pharmaceuticals

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round Undisclosed 3
Uniseed, Brandon Capital +1
01 Jan 2016

MetaBloQ Alternatives & Competitors

View All Alternatives
MetaBloQ vs

Pioneering innovative small molecules to disrupt metabolic and immune pathways, advancing therapeuti...

Series A
2-10 employees
Biopharma, Biotechnology
MetaBloQ vs

Pioneering novel therapies to address cancer and metabolic disorders by targeting essential cellular...

Debt Financing
Biotechnology, Health Care
MetaBloQ vs
Trethera
Trethera United States

Based in Santa Monica, CA, Trethera is a privately-held company that aims to develop safer, more aff...

Grant
6 employees
Biotechnology, Health Care

FAQ About MetaBloQ

Innovative biotechnological advancements for targeting metabolic pathways in cancer cells.
MetaBloQ was founded in 2015.
MetaBloQ operates in Biopharma, Biotechnology, Health Care and Pharmaceutical. Its work centres on metabolic pathways, cancer, drug development and metabolic processes.
MetaBloQ has completed 1 funding round. The latest funding stage is Seed.
Top alternatives and competitors to MetaBloQ include Nirogy Therapeutics, Petra Pharma, Trethera, Ribon Therapeutics, Calithera Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MetaBloQ and Nirogy Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for MetaBloQ, https://bouncewatch.com/company/metabloq, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes